Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

BACKGROUND: This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. METHODS: 148 mRCC patients were evaluated. According to Heng score 15.5%, 60.1% and 24.4% of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchini, Gaetano, Rossetti, Sabrina, Berretta, Massimiliano, Cavaliere, Carla, Scagliarini, Sarah, Vitale, Maria Giuseppa, Ciccarese, Chiara, Di Lorenzo, Giuseppe, Palesandro, Erica, Conteduca, Vincenza, Basso, Umberto, Naglieri, Emanuele, Farnesi, Azzurra, Aieta, Michele, Borsellino, Nicolò, La Torre, Leonardo, Iovane, Gelsomina, Bonomi, Lucia, Gasparro, Donatello, Ricevuto, Enrico, De Tursi, Michele, De Vivo, Rocco, Lo Re, Giovanni, Grillone, Francesco, Marchetti, Paolo, De Vita, Ferdinando, Scavelli, Claudio, Sini, Claudio, Pisconti, Salvatore, Crispo, Anna, Gebbia, Vittorio, Maestri, Antonio, Galli, Luca, De Giorgi, Ugo, Iacovelli, Roberto, Buonerba, Carlo, Cartenì, Giacomo, D’Aniello, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716812/
https://www.ncbi.nlm.nih.gov/pubmed/31464635
http://dx.doi.org/10.1186/s12967-019-2047-4

Ejemplares similares

Ejemplares similares